Moafi Alireza, Ziaie Mozhdeh, Abedi Marjan, Rahgozar Soheila, Reisi Nahid, Nematollahi Pardis, Moafi Hadi
Departmant of Pediatrics, School of Medicine, Isfahan University of Medical Sciences Department of Biology, Faculty of Sciences, University of Isfahan Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Department of Medicine, School of Medicine, University of Pécs, Pécs, Hungary.
Medicine (Baltimore). 2017 Nov;96(44):e8511. doi: 10.1097/MD.0000000000008511.
Iron is an intracellular element whose accumulation in the body is associated with tissue damage. This study examines the effect of iron on pediatric acute lymphoblastic leukemia (ALL) and its "response to treatment." At the end of the first year of treatment, bone marrow iron store (BMIS) was evaluated in children with ALL and the relationship between iron store and minimal residual disease was investigated. Moreover, the 3-year disease-free survival (3-DFS) of patients was determined. Patients' BMIS were compared with that of subjects with normal bone marrow. The study examined 93 children, including 78 Pre-B and 15 T-cell ALL patients. BMIS did not differ between the children with ALL and those with no evidence of cancer. BMIS was increased in 26.6% of patients at the end of the first year of treatment. Drug resistance and BM relapses were more prevalent in cases with high BMIS in both Pre-B and T-cell groups. Bone marrow iron store is not considered a risk factor for childhood ALL. However, high levels of BMIS are associated with poor response to treatment and the risk of relapse. Bone marrow iron store control during treatment can therefore help achieve better outcomes and improve the chances of recovery.
铁是一种细胞内元素，其在体内的蓄积与组织损伤相关。本研究探讨铁对小儿急性淋巴细胞白血病（ALL）及其“治疗反应”的影响。在治疗的第一年结束时，评估了ALL患儿的骨髓铁储存（BMIS），并研究了铁储存与微小残留病之间的关系。此外，还确定了患者的3年无病生存率（3-DFS）。将患者的BMIS与正常骨髓受试者的BMIS进行比较。该研究检查了93名儿童，包括78名前B细胞ALL和15名T细胞ALL患者。ALL患儿与无癌症证据的患儿之间的BMIS没有差异。在治疗的第一年结束时，26.6%的患者BMIS升高。在Pre-B和T细胞组中，BMIS高的病例中耐药性和骨髓复发更为普遍。骨髓铁储存不被认为是儿童ALL的危险因素。然而，高水平的BMIS与治疗反应不佳和复发风险相关。因此，治疗期间控制骨髓铁储存有助于取得更好的治疗效果并提高康复机会。
